Biocon’s arm to acquire Viatris’ Biosimilars Assets for up to $3.33 billion

Biopharmaceutical company Biocon on Monday announced that the board of directors of Biocon Biologics Limited, a material subsidiary of Biocon Limited, has approved the proposed acquisition of biosimilars assets of Viatris Inc. The transaction is subject to necessary regulatory and other approvals. Viatris will receive consideration of up to $3.335 billion, including cash up to … Read more

USFDA accepts Biocon-Mylan drug application for colon cancer

In a positive for Biocon, US drug regulator USFDA has accepted a biologics licence application by biopharmaceutical major and partner Mylan for a proposed biosimilar to treat advanced colon or rectal cancer. The application seeks approval of biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer in addition to other ailments. “Once approved, our … Read more